The FDA has granted accelerated approval to dostarlimab (Jemperli, made by GSK) for some patients with stage II or III rectal cancer, a decision that could let a small group of patients avoid surgery. The dostarlimab rectal cancer news was flagged Oct. 20 in a KFF Health News morning briefing that cited MedPage Today. It is an important step, and it also comes with real limits. This article is general information, not medical advice.
Dostarlimab rectal cancer approval: what we know so far
According to the KFF Health News briefing, the FDA’s accelerated approval covers some patients with stage II or III rectal cancer. The MedPage Today summary it relied on said the approval could allow those patients to skip surgery. It also said this group makes up about 3% of locally advanced cases.
Here is what we do not have. We have not seen the FDA label, so we cannot report the exact indication wording, the dose or the safety warnings. If you or a family member may be affected, read the label at fda.gov and go over it with an oncology team.
GSK had been moving toward this decision. Targeted Oncology and BioPharm International reported on Aug. 24, 2026 that the FDA had accepted the application with priority review. Fierce Pharma earlier described the filing as a small but high-profile cancer use for Jemperli following a positive phase 2 result.
Which rectal cancers are involved: dMMR and MSI-H tumors
This dostarlimab rectal cancer approval is not for every rectal cancer. The tumors in question are called mismatch repair deficient (dMMR), also described as microsatellite instability-high (MSI-H). In plain terms, the tumor cells have trouble fixing certain errors in their DNA, which leaves a distinctive genetic signature.
Reports say about 5% to 10% of rectal cancers show this profile. That range does not match the 3% figure above, and the difference is not a contradiction. The numbers use different denominators and framings. One describes the share of all rectal cancers with this profile, while the other describes the share of locally advanced cases covered by the approval, per MedPage Today’s summary. Treat any single percentage with care.
Why testing matters
A tumor sample can be tested for dMMR or MSI-H status, usually through a biopsy that is already taken for diagnosis. Testing is the gateway here. A patient whose tumor does not carry this profile would not be a candidate for this approach, which is why the result needs to be known before treatment is planned.
The evidence behind dostarlimab rectal cancer results
The strongest buzz for dostarlimab rectal cancer treatment comes from an early trial at Memorial Sloan Kettering (NCT04165772). It was presented at ASCO 2022 and published in the New England Journal of Medicine. Patients with stage II or III dMMR rectal cancer received dostarlimab 500 mg by IV every three weeks for six months, which is nine cycles.
The results were striking. According to OncLive’s coverage, all of the first 14 patients had a clinical complete response, meaning no tumor could be found on exam, endoscopy or MRI. Median follow-up was 6.8 months (range 0.7 to 23.8). No recurrences had been reported at that time. No patient needed chemoradiation or surgery, and no grade 3 or 4 adverse events were reported.
Those dostarlimab rectal cancer results sound almost too good, and the investigators said as much. Andrea Cercek of MSK said: “Longer follow-up is certainly required to establish the durability of this treatment.” Kimmie Ng of Dana-Farber called neoadjuvant dostarlimab for six months “a promising new treatment for patients with stage II/III dMMR rectal cancer,” and called for larger multicenter trials with survival endpoints.
The larger GSK trial
The dostarlimab rectal cancer approval is backed by GSK’s AZUR-1, a phase 2 trial in stage 2 or 3 dMMR/MSI-H locally advanced rectal cancer. Per the sources we reviewed, interim 12-month results showed a “meaningful and sustained” clinical complete response. No specific numbers were published in those sources, so we will not guess at them.
Two-year and three-year complete response, along with three-year event-free survival, are key secondary endpoints. Those later readouts will tell us a lot about how long the benefit lasts.
What accelerated approval means for patients
Accelerated approval is an FDA pathway for drugs that treat serious conditions and appear to fill an unmet need. In general, the FDA can approve such a drug based on a surrogate endpoint, an early measure that is reasonably likely to predict real clinical benefit, rather than waiting for final survival data.
The trade-off is that the company must run confirmatory trials. If those studies do not verify the benefit, the FDA can move to withdraw the approval. The agency explains its programs at fda.gov.
For this dostarlimab rectal cancer approval, the surrogate is essentially the complete response seen in the studies. It is a meaningful signal, but it is not the same as proof that patients live longer or stay cancer-free for decades. That is why the secondary endpoints in AZUR-1 matter so much.
Can dostarlimab rectal cancer treatment really mean “no surgery”?
The headline says patients may avoid surgery, and that is the hope. But “avoid surgery” needs unpacking.
First, a clinical complete response means doctors cannot see or feel a tumor using exams, endoscopy and MRI. It is not the same as a pathologic complete response, where a pathologist finds no cancer in removed tissue. Without surgery, there is no removed tissue to examine.
Second, skipping surgery generally means watch-and-wait surveillance. Patients are monitored on a schedule with exams, scopes and imaging to catch any regrowth early. In general, if a tumor returns, surgery or other treatment can still be discussed. This is general background, not a description of any one patient’s plan.
Third, the dostarlimab rectal cancer approval covers a narrow group. Most people with rectal cancer do not have a dMMR tumor, so for them standard treatment decisions are unchanged.
Surgical planning is a topic we have followed from other angles too. Our report on GLP-1 drugs before surgery and complication risk shows how much perioperative decisions depend on the individual patient.
Dostarlimab rectal cancer: questions to ask your oncology team
If you or someone you love has a rectal cancer diagnosis, these questions can help structure the conversation:
- Has my tumor been tested for mismatch repair deficiency or MSI-H status? What was the result?
- Am I a candidate for dostarlimab rectal cancer treatment under the new approval, based on my stage and the FDA label?
- What are the possible side effects of an immune checkpoint inhibitor, and how would they be monitored?
- What would a watch-and-wait schedule look like, and how often would I need scopes and scans?
- What happens if the tumor does not fully respond or comes back?
- How would this choice affect my options for chemoradiation or surgery later?
- Is there a clinical trial or a second opinion at a cancer center I should consider?
The National Cancer Institute at cancer.gov offers plain-language information on rectal cancer and clinical trials, and can help you prepare.
What is not yet known
Several important details are still missing from the sources we reviewed:
- The exact FDA label wording, dosing and safety warnings.
- For dostarlimab rectal cancer patients, the numeric response rate from AZUR-1 and how many patients it enrolled.
- How durable responses are beyond the early follow-up reported so far.
- How many patients will choose watch-and-wait, and how many will still have surgery later.
- Pricing, insurance coverage and access, which often vary by plan. Our guide to Medicare open enrollment and the 2027 drug cap is a useful starting point for older patients reviewing drug coverage.
The early MSK study was small, single-arm and short in follow-up, which means it had no comparison group. The investigators themselves said larger studies were needed. Both points are reasons for optimism and caution at once.
The takeaway
The dostarlimab rectal cancer approval is a genuine milestone for a small, genetically defined group of rectal cancer patients, and it shows how tumor biology is reshaping treatment. It is not a cure-all, and it does not apply to most people with rectal cancer.
The practical step for anyone facing dostarlimab rectal cancer decisions is simple. Ask whether your tumor has been tested for dMMR or MSI-H, read the FDA label for the exact indication, and talk through surveillance, risks and alternatives with your oncology team before deciding. Staying on top of other health research can help too, such as our look at a high-fiber diet versus metformin trial. This article is for general information only and is not medical advice.
